ES2160626T3 - Inmunomodulador, inhibidor de la adherencia celular, y agente que permite tratar y prevenir enfermedades autoinmunes. - Google Patents

Inmunomodulador, inhibidor de la adherencia celular, y agente que permite tratar y prevenir enfermedades autoinmunes.

Info

Publication number
ES2160626T3
ES2160626T3 ES94912070T ES94912070T ES2160626T3 ES 2160626 T3 ES2160626 T3 ES 2160626T3 ES 94912070 T ES94912070 T ES 94912070T ES 94912070 T ES94912070 T ES 94912070T ES 2160626 T3 ES2160626 T3 ES 2160626T3
Authority
ES
Spain
Prior art keywords
autoimmune diseases
disease
autoimmune
general formula
cell adhesion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94912070T
Other languages
English (en)
Inventor
Keiichi Tanaka
Shinji Makino
Ichiro Oshio
Tomoya Shimotori
Yukihiko Aikawa
Takihiro Inaba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyama Chemical Co Ltd
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Application granted granted Critical
Publication of ES2160626T3 publication Critical patent/ES2160626T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

Abstract

UN DERIVADO DE 4H-1-BENZOPIRAN-4-ONA DE LA FORMULA GENERAL [1], O UNA SAL DEL MISMO QUE EJERCE UNOS EFECTOS EXCELENTES DE INMUNOMODULACION Y DE INHIBICION DE LA ADHESION CELULAR Y SE ESPERA QUE POSEA TAMBIEN EL EFECTO DE ALIVIAR LAS ENFERMEDADES AUTOINMUNES A UN NIVEL COMPARABLE AL DE LOS ESTEROIDES. POR TANTO, EL COMPUESTO DE LA FORMULA GENERAL [1] ES UTIL PARA EL TRATAMIENTO Y PREVENCION DE ENFERMEDADES AUTOINMUNES CAUSADAS FUNDAMENTALMENTE POR UNA INMUNOPATIA O UNA ADHESION CELULAR ACELERADA DE FORMA ANORMAL, POR EJEMPLO, ARTRITIS REUMATICA CRONICA, ERICEMATOSIS DE LUPUS SISTEMICO, ESCLEREMAS, ENFERMEDADES DEL TEJIDO CONJUNTIVO MIXTO, POLIARTERITIS NUDOSA, LA POLIMIOSITIS/DERMATOMIOSITIS, SINDROME DE SJOGREN, ENFERMEDAD DE BEHCET, ESCLEROSIS MULTIPLE, DIABETES AUTOINMUNE, ENFERMEDAD DE HASHIMOTO, PSORIASIS, MIXEDEMA PRIMARIO, ANEMIA PERNICIOSA, ADINAMIA AGUDA, COLITIS ULCERATIVA, HEPATITIS CRONICA ACTIVA, ANEMIA HEMOLITICA AUTOINMUNE Y PURPURA TROMBOCITOPENICA IDIOPATICA.
ES94912070T 1993-04-09 1994-04-07 Inmunomodulador, inhibidor de la adherencia celular, y agente que permite tratar y prevenir enfermedades autoinmunes. Expired - Lifetime ES2160626T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10746493 1993-04-09

Publications (1)

Publication Number Publication Date
ES2160626T3 true ES2160626T3 (es) 2001-11-16

Family

ID=14459856

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94912070T Expired - Lifetime ES2160626T3 (es) 1993-04-09 1994-04-07 Inmunomodulador, inhibidor de la adherencia celular, y agente que permite tratar y prevenir enfermedades autoinmunes.

Country Status (14)

Country Link
US (2) US5922755A (es)
EP (1) EP0695547B1 (es)
JP (1) JP3521145B2 (es)
KR (1) KR960701633A (es)
AT (1) ATE203904T1 (es)
AU (1) AU698990B2 (es)
CA (1) CA2159192C (es)
DE (1) DE69427907T2 (es)
DK (1) DK0695547T3 (es)
ES (1) ES2160626T3 (es)
GR (1) GR3036738T3 (es)
NZ (1) NZ263620A (es)
PT (1) PT695547E (es)
WO (1) WO1994023714A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US7001921B1 (en) 1995-01-23 2006-02-21 Biogen Idec Ma Inc. Cell adhesion inhibitors
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
US6239108B1 (en) 1996-07-11 2001-05-29 Biogen, Inc. Cell adhesion inhibitors
DE69737769T2 (de) 1996-07-25 2008-05-15 Biogen Idec Ma Inc., Cambridge Molekülmodell für vla-4-inhibitoren
US6686350B1 (en) 1996-07-25 2004-02-03 Biogen, Inc. Cell adhesion inhibitors
NZ509199A (en) 1998-05-28 2003-10-31 Biogen Inc A VLA-4 inhibitor: oMePUPA-V
JP2001055331A (ja) * 1999-06-11 2001-02-27 Toyama Chem Co Ltd アトピー性皮膚炎治療剤
CZ2002518A3 (cs) * 1999-08-13 2002-05-15 Biogen, Inc. Inhibitory buněčné adheze a farmaceutické prostředky, které je obsahují
WO2002020509A2 (de) * 2000-09-06 2002-03-14 Bayer Aktiengesellschaft Arzneimittel gegen virale erkrankungen
US6875743B1 (en) 2000-11-28 2005-04-05 Biogen, Inc. Cell adhesion inhibitors
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119863D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
JP3972663B2 (ja) * 2002-01-22 2007-09-05 松下電器産業株式会社 高周波信号受信装置
US7049313B2 (en) * 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
CN100387231C (zh) * 2003-03-24 2008-05-14 天津药物研究院 一种制备古拉替莫固体制剂的工艺及其固体制剂
CN1867566B (zh) * 2003-08-13 2010-06-16 库多斯药物有限公司 氨基吡喃酮和它们作为atm抑制剂的用途
WO2005115992A1 (en) 2004-05-23 2005-12-08 Housey Pharmaceuticals, Inc. Theramutein modulators
US7196112B2 (en) * 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
US7402607B2 (en) 2004-09-20 2008-07-22 Kudos Pharmaceuticals Limited DNA-PK inhibitors
TW200638938A (en) * 2005-02-09 2006-11-16 Kudos Pharm Ltd ATM inhibitors
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
TW200745094A (en) * 2005-08-31 2007-12-16 Kudos Pharm Ltd ATM inhibitor
JP4659769B2 (ja) * 2007-01-25 2011-03-30 トヨタ自動車株式会社 冷却装置
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
EP2752190B1 (en) 2011-08-30 2021-03-03 Toyama Chemical Co., Ltd. Method for improving therapy for autoimmune diseases such as rheumatoid arthritis
TWI583677B (zh) * 2012-09-21 2017-05-21 日本臟器製藥股份有限公司 香豆素衍生物
DK2929880T3 (da) * 2013-07-18 2017-01-02 Toyama Chemical Co Ltd Terapeutisk middel til sygdom baseret på hæmmende effekt af makrofag-migrationshæmmende faktor
CN106102736A (zh) 2014-02-14 2016-11-09 富山化学工业株式会社 脑内淀粉样蛋白‑β蓄积病的预防或治疗药
JP6089055B2 (ja) * 2014-03-20 2017-03-01 日本臓器製薬株式会社 クマリン誘導体を含有する医薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
GB8907799D0 (en) * 1989-04-06 1989-05-17 Erba Carlo Spa Heteroaryl-3-oxo-propanenitrile derivatives useful in the treatment of rheumatoid arthritis and other autoimmune diseases
JP3086312B2 (ja) * 1991-10-28 2000-09-11 富山化学工業株式会社 インターロイキン６の産生抑制剤並びにその産生抑制作用が有効な疾患の治療・予防剤

Also Published As

Publication number Publication date
GR3036738T3 (en) 2001-12-31
EP0695547A1 (en) 1996-02-07
DK0695547T3 (da) 2001-10-08
EP0695547B1 (en) 2001-08-08
ATE203904T1 (de) 2001-08-15
US6166068A (en) 2000-12-26
KR960701633A (ko) 1996-03-28
CA2159192C (en) 2006-07-25
AU6437194A (en) 1994-11-08
US5922755A (en) 1999-07-13
PT695547E (pt) 2001-12-28
EP0695547A4 (en) 1997-05-28
AU698990B2 (en) 1998-11-19
DE69427907T2 (de) 2002-04-04
CA2159192A1 (en) 1994-10-27
WO1994023714A1 (en) 1994-10-27
NZ263620A (en) 1999-06-29
JP3521145B2 (ja) 2004-04-19
DE69427907D1 (de) 2001-09-13

Similar Documents

Publication Publication Date Title
ES2160626T3 (es) Inmunomodulador, inhibidor de la adherencia celular, y agente que permite tratar y prevenir enfermedades autoinmunes.
TWI256408B (en) Novel ester compounds
AU1086492A (en) Modified cementitious composition
NO173992C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive benzocykloalkenyldihydroksyalkansyrederivater
CA2218028A1 (en) Brain edema inhibitor
HUP9900865A2 (hu) Vírusellenes hatású benzimidazolszármazékok, előállításuk és alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények
ES2074828T3 (es) Copoliester degradable de 4-hidroxi-prolina y composicion farmaceutica que lo contiene.
EP0118132A3 (en) A remedial or prophylactic agent for the treatment of seizures
EP0491041A4 (en) Antiviral drug
KR900000726A (ko) 방사선-감응 혼합물 및 이로부터 생성된 방사선-감응 복사물질
FI900796A0 (fi) Aralkylaminfoereningar.
ES8404679A1 (es) Procedimiento para preparar un derivado de nitroimidazol.
KR910007845A (ko) 디사이클로헥실에틸렌 유도체
DE3864660D1 (en) Thiophen-derivate.
FI956334A0 (fi) Farmakologisesti aktiivisia enantiomeereja
GB2071098B (en) Dibenzocycloheptenylidenes and antiinflammatory compositions
DE58900265D1 (de) Klebstoff.
BR9714497A (pt) Derivados de piperidinadiona substituìda, e, herbicidas.
ATE71364T1 (de) Fluor enthaltende vitamin-d2-derivate.
ES1019852U (es) Pieza para fijacion de una chapa o perfil.
EP0086756A3 (en) Dermatological compositions based on mercaptopropionylamidoacetic thiol esters
HUP9603631A2 (hu) Gyógyszerkészítmény
TH17660EX (th) สารผสมสำหรับป้องกันและรักษาสายตาสั้น

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 695547

Country of ref document: ES